Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
BUPRENORPHINE
BARD PHARMACEUTICALS (1990) INC
N02AE01
BUPRENORPHINE
20MCG
PATCH
BUPRENORPHINE 20MCG
TRANSDERMAL
100
Narcotic (CDSA I)
OPIATE PARTIAL AGONISTS
Active ingredient group (AIG) number: 0142241019; AHFS:
APPROVED
2019-11-01
_ _ _BAR-Buprenorphine (buprenorphine transdermal patch) _ _ _ _Page 1 of 71 _ _ _ PRODUCT MONOGRAPH N BAR-BUPRENORPHINE Buprenorphine Transdermal System 5, 10, 15 and 20 mcg/h Manufacturer’s Standard Opioid Analgesic Bard Pharmaceuticals (1990) Inc. 575 Granite Court Pickering, Ontario L1W 3W8 DATE OF REVISION: November 1, 2019 Submission Control No: 231026 BUTRANS ® is a trademark of Purdue Pharma _ _ _BAR-Buprenorphine (buprenorphine transdermal patch) _ _ _ _Page 2 of 71 _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................. 3 INDICATIONS AND CLINICAL USE ........................................................................ 3 CONTRAINDICATIONS ............................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................ 5 ADVERSE REACTIONS ............................................................................................ 18 DRUG INTERACTIONS ............................................................................................ 30 DOSAGE AND ADMINISTRATION ........................................................................ 32 OVERDOSAGE ........................................................................................................... 37 ACTION AND CLINICAL PHARMACOLOGY ...................................................... 38 STORAGE AND STABILITY .................................................................................... 43 SPECIAL HANDLING INSTRUCTIONS ................................................................. 43 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................... 43 AVAILABILITY OF DOSAGE FORMS ................................................................... 44 PART II: SCIENTIFIC INFORMATION ....................................................... Soma hati kamili